SILO Latest Report
1min read Financial Performance
Silo Pharma's operating revenue totaled RMB18,026,000 as of December 31, 2024, a significant improvement from its negative operating revenue (-RMB1,813,352) in 2023. This indicates a significant improvement in the company's ability to generate revenue, despite the operating difficulties in 2023, and the recovery in 2024 suggests the potential for market recovery.
Ask Aime: Silo Pharma's Financial Performance Improvement
Key Financial Data
1. The operating revenue has turned from negative to positive, indicating the company's market recovery and growth potential.
2. The sales cost was RMB1,460,000, with a gross profit of RMB16,566,000, showing the company's effectiveness in cost control.
3. The research and development expenses increased to RMB1,075,719, reflecting the company's active investment in new product development and technological innovation.
4. The changes in market environment may be affected by the improvement of macroeconomics and industry policy benefits.
Peer Comparison
1. Industry-wide analysis: The overall market demand for the biopharmaceutical industry has recovered, and policy support may lead to a general rebound in operating revenue, reflecting the overall recovery trend of the industry.
2. Peer evaluation analysis: silo pharma achieved positive revenue in 2024, showing the recovery of its market competitiveness, compared to the negative revenue in 2023, indicating an improvement in its position.
Summary
Silo Pharma's significant improvement in operating revenue in 2024 indicates its positive performance in the changing market environment. Despite the challenges, the company has demonstrated its potential for future growth through effective cost control and research and development investment.
Opportunities
1. Continue to strengthen R&D investment, especially in new drug development, to adapt to market demand and enhance competitiveness.
2. Take advantage of policy support opportunities and actively adjust business strategies to seize opportunities brought by market changes.
3. Focus on the overall recovery trend of the industry and explore multi-channel layout to enhance market penetration.
Risks
1. Changes in market regulatory policies may have a negative impact on the company's operations, and it is necessary to pay close attention to policy developments.
2. The improvement of operating performance by other companies in the industry may increase competition pressure and affect market share.
3. The progress of R&D projects may fail to meet expectations, which may have a negative impact on future revenue growth.
